Trial Profile
Prospective observational study of biomarkers to predict efficacy after Nivolumab in patients with previously treated advanced non-small cell lung cancer.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics
- Sponsors Bristol-Myers K.K.; Ono Pharmaceutical
- 27 May 2016 New trial record